



New Potent Antibacterial Agents

Guest Editor:

Prof. Dr. Muriel Masi

1. MCT, INSERM U1261,
UMR_MD1, Aix-Marseille
University & IRBA SSA, 27
Boulevard Jean Moulin, 13005
Marseille, France
2. Synchrotron SOLEIL, L'Orme
des Merisiers, Départementale
128, 91190 Saint-Aubin, France

Deadline for manuscript
submissions:

closed (30 July 2021)

Message from the Guest Editor

Bacteria have developed several mechanisms to circumvent antibiotic activity, causing therapeutic failures. Faced with the worldwide problem of antibiotic resistance, there is an urgent need to discover and develop new antibacterial agents.

In this Special Issue, new potent antibacterial agents with mechanical and structural varieties will be considered as therapeutic approaches to defeat both Gram-positive and Gram-negative pathogens. We will cover the development of new antibiotics resulting from research on medicinal chemistry and synthetic biology, bioactive agents such as bacteriophages and bacteriocins, antibiotic interactions, and adjuvants that target the bacterial lifecycle (such as virulence and communication) or drug resistance mechanisms (such as antibiotic efflux and permeation). All types of articles falling within the scope of the above research areas are welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)